tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MicroPort’s Endovastec Reports Mixed Financial Results for H1 2025

Story Highlights
  • MicroPort Scientific focuses on endovascular and cardiovascular medical technologies.
  • Endovastec reported decreased revenue and profit but increased assets and equity in H1 2025.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
MicroPort’s Endovastec Reports Mixed Financial Results for H1 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from MicroPort Scientific ( (HK:0853) ) is now available.

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., a subsidiary of MicroPort Scientific, reported a decline in revenue and profit for the first half of 2025 compared to the same period in 2024. Despite a decrease in financial performance, the company’s total assets and equity showed growth, indicating a mixed impact on its operations and potential implications for stakeholders.

The most recent analyst rating on (HK:0853) stock is a Buy with a HK$17.20 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.

More about MicroPort Scientific

MicroPort Scientific is a company engaged in the medical technology industry, focusing on the development and manufacturing of medical devices. Its primary products and services include endovascular and cardiovascular medical technologies, with a market focus on innovative solutions for healthcare.

Average Trading Volume: 44,398,062

Technical Sentiment Signal: Buy

Current Market Cap: HK$23.95B

For a thorough assessment of 0853 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1